Synaptogenix Responds to FDA Approval of Aducanumab ...Middle East

NEW YORK, June 7, 2021 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today issued a statement following the announced FDA approval of Biogen's new Alzheimer's treatment Aducanumab....

Hence then, the article about synaptogenix responds to fda approval of aducanumab was published today ( Monday 07/06/2021 - 07:00 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Synaptogenix Responds to FDA Approval of Aducanumab )

Also on site :

• Greenland hit by power outage, strong winds in wake of US tensions easing
• Cuban official accuses US of ‘piracy’ against sanctioned Caribbean island
• Numbrix 9 - January 25